目的 探究冠心寧片聯(lián)合鹽酸艾司洛爾注射液治療不穩(wěn)定型心絞痛的臨床療效。方法 選取2015年1月-2016年6月鳳翔縣醫(yī)院收治的不穩(wěn)定性心絞痛患者86例為研究對象，所有患者隨機分為對照組（46例）和治療組（40例）。對照組靜脈注射鹽酸艾司洛爾注射液0.5 mg/（kg·min），1 min后以0.05 mg/（kg·min）靜脈滴注維持，治療中根據(jù)心功能情況隨時調(diào)整給藥速度。治療組在對照組的基礎(chǔ)上口服冠心寧片，3片/次，3次/d。兩組患者連續(xù)治療8周。觀察兩組的臨床療效，比較兩組心絞痛發(fā)作次數(shù)、持續(xù)時間、血清超敏C反應(yīng)蛋白（hs-CRP）、基質(zhì)金屬蛋白酶-9（MMP-9）和B型利鈉肽（BNP）水平。結(jié)果 治療后，對照組和治療組的總有效率分別為71.74%、90.00%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，對照組和治療組的心電圖總有效率分別為32.61%、52.50%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組心絞痛發(fā)作次數(shù)和心絞痛持續(xù)時間明顯降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組hs-CRP、MMP-9和BNP水平顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組這些觀察指標明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 冠心寧片聯(lián)合鹽酸艾司洛爾注射液治療不穩(wěn)定型心絞痛具有較好的臨床療效，可改善臨床癥狀，降低hs-CRP、MMP-9和BNP水平，安全性較好，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical effect of Guanxinning Tablets combined with Esmolol Hydrochloride Injection in treatment of unstable angina pectoris. Methods Patients (86 cases) with unstable angina pectoris in Fengxiang County Hospital from January 2015 to June 2016 were randomly divided into the control group (46 cases) and treatment group (40 cases). Patients in the control group were iv administered with Esmolol Hydrochloride Injection 0.5 mg/(kg·min), maintenance dose of 0.05 mg/(kg·min) after 1 min according to the cardiac function to adjust the injection speed. Patients in the treatment group were po administered with Guanxinning Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and angina pectoris frequency, pectoris duration, and the level of hs-CRP, MMP-9, and BNP in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 71.74% and 90.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 32.61% and 52.50%, respectively, and there was difference between two groups (P<0.05). After treatment, angina pectoris frequency and pectoris duration in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP, MMP-9, and BNP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Guanxinning Tablets combined with Esmolol Hydrochloride Injection has clinical curative effect in treatment of unstable angina pectoris, can improve clinical symptoms, and decrease level of hs-CRP, MMP-9, and BNP, with good safety, which has a certain clinical application value.